NZ601001A - Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue - Google Patents

Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue

Info

Publication number
NZ601001A
NZ601001A NZ601001A NZ60100110A NZ601001A NZ 601001 A NZ601001 A NZ 601001A NZ 601001 A NZ601001 A NZ 601001A NZ 60100110 A NZ60100110 A NZ 60100110A NZ 601001 A NZ601001 A NZ 601001A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutical composition
solvent mixture
esters
solvent
group
Prior art date
Application number
NZ601001A
Other languages
English (en)
Inventor
Karsten Petersson
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of NZ601001A publication Critical patent/NZ601001A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ601001A 2009-12-22 2010-12-22 Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue NZ601001A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK2009000264 2009-12-22
US29310810P 2010-01-07 2010-01-07
PCT/DK2010/000184 WO2011076209A2 (en) 2009-12-22 2010-12-22 Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue

Publications (1)

Publication Number Publication Date
NZ601001A true NZ601001A (en) 2014-07-25

Family

ID=43618136

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ601001A NZ601001A (en) 2009-12-22 2010-12-22 Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue

Country Status (14)

Country Link
US (1) US20130023501A1 (https=)
EP (1) EP2515866B1 (https=)
JP (1) JP5732471B2 (https=)
CN (1) CN102770121B (https=)
AU (1) AU2010335656B2 (https=)
BR (1) BR112012015437A2 (https=)
CA (1) CA2785254A1 (https=)
ES (1) ES2452872T3 (https=)
IL (1) IL220517A (https=)
MX (1) MX2012007225A (https=)
NZ (1) NZ601001A (https=)
RU (1) RU2559084C2 (https=)
WO (1) WO2011076209A2 (https=)
ZA (1) ZA201204622B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630169A (en) * 2013-02-27 2017-07-28 Laurie Robert Batt Anhydrous transdermal formulations
KR102486797B1 (ko) * 2016-03-09 2023-01-11 삼성전자 주식회사 전자 장치 및 전자 장치의 디스플레이 구동 방법
CN107643354B (zh) * 2016-07-22 2022-02-01 重庆华邦胜凯制药有限公司 卡泊三醇起始原料a及相关杂质的分离与测定方法
CN106265485A (zh) * 2016-08-22 2017-01-04 江苏知原药业有限公司 一种稳定性改善的卡泊三醇组合物
CN106265511A (zh) * 2016-08-22 2017-01-04 江苏知原药业有限公司 一种性能优异的卡泊三醇倍他米松自微乳制剂
CN108904445A (zh) * 2018-08-06 2018-11-30 江苏知原药业有限公司 钙泊三醇纳米悬浮液
CA3157812C (en) * 2019-10-25 2024-10-22 Cardiol Therapeutics Inc. Cannabidiol compositions for use in treating heart conditions
BR112023001283A2 (pt) 2020-07-28 2023-02-14 Arcutis Biotherapeutics Inc Composição farmacêutica tópica; método para tratar uma doença, distúrbio ou afecção inflamatória de pele em um indivíduo que necessita do mesmo; e método para intensificar a penetração em pele em um indivíduo de uma formulação farmacêutica tópica
KR20240125610A (ko) 2021-12-15 2024-08-19 아큐티스 바이오테라퓨틱스, 인크. Shr0302의 안정된 제형

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4083974A (en) * 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
DE4011682A1 (de) * 1990-04-06 1991-10-10 Schering Ag 24-oxa-derivate in der vitamin d-reihe
US5194431A (en) * 1992-07-08 1993-03-16 Wisconsin Alumni Research Foundation 24-cyclopropane vitamin D derivatives
GB9300763D0 (en) 1993-01-15 1993-03-03 Leo Pharm Prod Ltd Chemical compound
GB9611603D0 (en) * 1996-06-04 1996-08-07 Leo Pharm Prod Ltd Chemical compounds
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
PL199123B1 (pl) * 1999-04-23 2008-08-29 Leo Pharm Prod Ltd Niewodna kompozycja farmaceutyczna do stosowania naskórnego i jej zastosowanie
BR0214679A (pt) * 2001-12-03 2004-12-14 Novacea Inc Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
DK1658263T3 (da) 2003-07-24 2010-09-27 Leo Pharma As Aminobenzophenonforbindelser
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
FR2871694B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises
KR101260236B1 (ko) 2004-12-13 2013-05-06 레오 파마 에이/에스 트리아졸 치환된 아미노벤조페논 화합물
FR2887150B1 (fr) * 2005-06-17 2007-08-03 Galderma Res & Dev Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise
FR2909284B1 (fr) * 2006-11-30 2012-09-21 Galderma Sa Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
EP2125736B1 (en) 2006-12-22 2011-03-30 Leo Pharma A/S Substituted acetophenones useful as pde4 inhibitors
CA2676933C (en) 2007-02-28 2015-09-29 Leo Pharma A/S Novel phosphodiesterase inhibitors
US7909624B2 (en) 2007-03-26 2011-03-22 Belkin International, Inc. Carabiner universal serial bus hub
JP2010524864A (ja) 2007-04-19 2010-07-22 レオ ファーマ アクティーゼルスカブ Srcファミリーキナーゼ阻害剤
PL2148661T3 (pl) * 2007-04-25 2013-07-31 Cytochroma Inc Doustne kompozycje o kontrolowanym uwalnianiu zawierające związek będący witaminą D i woskowy nośnik
CA2685516A1 (en) 2007-05-11 2008-11-20 Sonneborn Inc. Petrolatums having silicone-like properties
RU2544011C2 (ru) 2008-12-19 2015-03-10 Лео Фарма А/С Триазолопиридины в качестве ингибиторов фосфодиэстеразы для лечения кожных заболеваний

Also Published As

Publication number Publication date
EP2515866A2 (en) 2012-10-31
EP2515866B1 (en) 2014-02-19
CN102770121B (zh) 2014-10-15
JP5732471B2 (ja) 2015-06-10
AU2010335656A1 (en) 2012-07-19
JP2013515020A (ja) 2013-05-02
MX2012007225A (es) 2012-07-30
BR112012015437A2 (pt) 2016-03-15
WO2011076209A2 (en) 2011-06-30
RU2012130411A (ru) 2014-01-27
ZA201204622B (en) 2013-09-25
ES2452872T3 (es) 2014-04-03
HK1177696A1 (en) 2013-08-30
RU2559084C2 (ru) 2015-08-10
IL220517A (en) 2016-08-31
IL220517A0 (en) 2012-08-30
CA2785254A1 (en) 2011-06-30
CN102770121A (zh) 2012-11-07
AU2010335656B2 (en) 2015-05-07
US20130023501A1 (en) 2013-01-24
WO2011076209A3 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
NZ601001A (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
EA201171371A1 (ru) Полиненасыщенные жирные кислоты для лечения заболеваний, связанных с сердечно-сосудистыми, метаболическими и воспалительными заболеваниями
BR112012030653A2 (pt) composição tópica em aerosol, estável ao armazenamento e substancialmente anidra, e, recipiente pressurizado
HN2012001744A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
CO6341548A2 (es) Nuevos lipidos que contienen azufre para el uso como suplemento alimenticio o como medicamento
CO6220926A2 (es) Formulacion farmaceutica topica para la aplicacion de un farmaco antiinflamatorio no esferoidal (nsaid)
NZ743706A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
AR082443A1 (es) Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa
WO2009038110A1 (ja) 神経栄養因子様作用剤
NZ596228A (en) Compositions and methods for the treatment of inflammation
PH12014502823A1 (en) Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
BR112013020167A2 (pt) melhoradores de permeação para formulações tópicas
WO2008115069A3 (en) Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents
AR078785A1 (es) Formulaciones de bazedoxifeno con antioxidantes
MX2014001065A (es) Formulaciones de (trimetoxifenilamino) pirimidilino nuevas.
WO2009116086A3 (en) Topical formulation comprising adapalene microspheres and clindamycin
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
WO2009111688A3 (en) All-trans retinoid esters as active pharmaceutical ingredients, oral and topical dosage form compositions thereof, and methods of treating skin conditions thereof
MY151002A (en) Polyunsaturated fatty acid and diol ester as an anti-acne agent
ECSP13012369A (es) Agentes terapéuticos 976
NZ603476A (en) Topical pharmaceutical composition comprising heparin
PH12014502817A1 (en) Compounds from the fruits of acrocomia crispa and acrocomia aculeata for use against oxidative stress and inflammation
WO2010032041A3 (en) Antibacterial and/or anti-acne formulations containing salicylic acid or a derivative thereof
MX2010012927A (es) Una mezcla solubilizante, solucion farmaceutica para tratar otitis y su metodo de preparacion.
NZ619990A (en) Animal supplements and compositions containing soluble monensin and methods therefor

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2015 BY COMPUTER PACKAGES INC

Effective date: 20141202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2016 BY COMPUTER PACKAGES INC

Effective date: 20151201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2017 BY COMPUTER PACKAGES INC

Effective date: 20161201

LAPS Patent lapsed